Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10651484rdf:typepubmed:Citationlld:pubmed
pubmed-article:10651484lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C1705280lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0235974lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0525037lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0205396lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C1879313lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10651484lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10651484pubmed:issue3lld:pubmed
pubmed-article:10651484pubmed:dateCreated2000-1-24lld:pubmed
pubmed-article:10651484pubmed:abstractTextGerm-line mutations in the p16/CDKN2 gene are known to predispose to melanoma. This gene belongs to a family of cyclin-dependent kinase inhibitors and blocks G1-S progression. The occurrence of p16/CDKN2 germline mutations in 12 Icelandic melanoma kindreds (kindreds with two or more cases of melanoma or melanoma, pancreas and/or glioma cases) was examined. No germ-line mutation was found, however five mutations not previously discribed in solid tumours were identified, Pro48Leu, Ala57Val, Gly89Asp, Leu117Met, Tyr129Stop.lld:pubmed
pubmed-article:10651484pubmed:languageenglld:pubmed
pubmed-article:10651484pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10651484pubmed:citationSubsetIMlld:pubmed
pubmed-article:10651484pubmed:statusMEDLINElld:pubmed
pubmed-article:10651484pubmed:issn1059-7794lld:pubmed
pubmed-article:10651484pubmed:authorpubmed-author:BornJJlld:pubmed
pubmed-article:10651484pubmed:authorpubmed-author:OlafsdóttirG...lld:pubmed
pubmed-article:10651484pubmed:authorpubmed-author:Gretarsdóttir...lld:pubmed
pubmed-article:10651484pubmed:issnTypePrintlld:pubmed
pubmed-article:10651484pubmed:volume12lld:pubmed
pubmed-article:10651484pubmed:ownerNLMlld:pubmed
pubmed-article:10651484pubmed:authorsCompleteYlld:pubmed
pubmed-article:10651484pubmed:pagination212lld:pubmed
pubmed-article:10651484pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:meshHeadingpubmed-meshheading:10651484...lld:pubmed
pubmed-article:10651484pubmed:year1998lld:pubmed
pubmed-article:10651484pubmed:articleTitleFive novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas. Mutations in brief no. 170. Online.lld:pubmed
pubmed-article:10651484pubmed:affiliationMolecular and Cell Biology Reseach Laboratory, Reykjavik, Iceland. solveig@krabb.islld:pubmed
pubmed-article:10651484pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:1029entrezgene:pubmedpubmed-article:10651484lld:entrezgene